choline acetyltransferase [CAT]
An enzyme that controls the production of acetylcholine; appears to be depleted in the brains of individuals with Alzheimer’s disease.
- Alzheimer Europe
- Our work
- Aims
- Strategic Plan (2011-2015)
- 2013 Work Plan
- Current projects
- Annual Reports
- Completed AE projects
- 2011: Legislation relating to restrictions of freedom
- 2011: The ethics of dementia research
- 2010: The ethical issues linked to the use of assistive technology in dementia care
- 2010: Legislation relating to legal capacity and proxy decision making
- 2009: Legislation relating to healthcare and decision making in dementia
- 2006-2008: EuroCoDe
- 2006: Dementia Carers' Survey
- 2004-2005: Advance directives
- 2004-2005: Support after diagnosis
- 2002-2003: Rare forms of dementia
- 2002-2003: Optimisation of the diagnosis of Alzheimer's disease and related disorders (OPDAL)
- 2000-2001: Equality in home care provision
- 1998-2000: Intranet
- 1997-2000: Lawnet
- 1997-1999: Children's book
- 1997: Rural areas
- 1997: Early onset dementia
- 1996-1998: Care Manual
- 1996-1998: ERICA
- 1995-1997: Telephone Helpline
- Who we are
- Statutes and Finances
- Our partners
- Alzheimer Europe publications
- Contact us
- Our work
- Dementia
- A-Z of dementias
- Alzheimer's disease
- Who is affected by Alzheimer's disease?
- Is Alzheimer's disease hereditary?
- Is there a test that can predict Alzheimer's disease?
- How is Alzheimer's disease diagnosed?
- Is there any treatment for Alzheimer's disease
- Main characteristics of Alzheimer's disease
- What kind of research has been carried out?
- Other forms of dementia
- Neuro-Degenerative Diseases
- Familial Alzheimer's disease
- Dementia with Lewy Bodies (DLB)
- Dementia in Parkinson's disease (PDD)
- Fronto-Temporal Degeneration
- Progressive Supranuclear Palsy (PSP)
- Corticobasal degeneration (CBD)
- Argyrophilic Grain Disease (AGD)
- Multiple System Atrophy (MSA)
- Amyotrophic Lateral Sclerosis (ALS)
- Ataxias
- Huntington's Disease (HD)
- Down syndrome
- Familial British dementia
- Infectious Diseases
- Metabolic Diseases
- Traumatic Diseases
- Toxic Diseases
- Cerebro-Vascular Diseases
- Other Rare Causes of Dementia
- Neuro-Degenerative Diseases
- Living with dementia
- After diagnosis - What next?
- Caring for someone with dementia
- Personal experiences of living with dementia
- Contact your national Alzheimer Association
- Policy in Practice
- Paris Declaration
- European Alzheimer's Alliance
- Members
- Alliance activities
- December 2012: “Living with dementia: Learning from the experiences of people with dementia.”
- June 2012: "Alzheimer's disease in the new European public health and research programmes"
- February 2012: "IMI in the spotlight" & "Speeding up drug discovery for Alzheimer’s disease: the PharmaCog project"
- December 2011: "Public perceptions of Alzheimer’s disease and the value of diagnosis"
- June 2011: "The Alzheimer Cooperative Valuation in Europe"
- March 2011: "European activities on long-term care: What implications for people with dementia and their carers?"
- December 2010: "The Joint Programming of research in Neurodegenerative Diseases (JPND). What progress so far?"
- June 2010: “Alzheimer’s disease and dementia as a national priority: contrasting approaches by France and the UK”
- September 2009: "European Action on dementia"
- March 2009: "Towards a European Action Plan on Alzheimer's disease"
- December 2008 "The rising cost of dementia"
- September 2008: Launch of Written Declaration
- September 2008: "Current and future treatments for AD"
- MEPs speak out on dementia
- Jan Andersson (Sweden)
- Elena Oana Antonescu (Romania)
- Maria Badia i Cutchet (Spain)
- John Bowis (United Kingdom)
- Frieda Brepoels (Belgium)
- Milan Cabrnoch (Czech Republic)
- Michael Cashman (United Kingdom)
- Nessa Childers (Ireland)
- Ole Christensen (Denmark)
- Brian Crowley (Ireland)
- Karl-Heinz Florenz (Germany)
- Françoise Grossetête (France)
- Maria Eleni Koppa (Greece)
- Katalin Levai (Hungary)
- Astrid Lulling (Luxembourg)
- Jan Tadeusz Masiel (Poland)
- Marisa Matias (Portugal)
- Linda McAvan (United Kingdom)
- Claude Moraes (United Kingdom)
- Elisabeth Morin-Chartier (France)
- Marie Panayotopoulos-Cassiotou (Greece)
- Antonyia Parvanova (Bulgaria)
- Sirpa Pietikäinen (Finland)
- Frédérique Ries (Belgium)
- Dagmar Roth-Behrendt (Germany)
- Keith Taylor (UK)
- Patrizia Toia (Italy)
- Kathy Sinnott (Ireland)
- Angelika Werthmann (Austria)
- Glenis Willmott (UK)
- Corien Wortmann-Kool (Netherlands)
- Marina Yannakoudakis (UK)
- Anna Záborská (Slovakia)
- Dushana Zdravkova (Bulgaria)
- Past supporters
- EU Presidencies
- EU Action on Dementia
- National Dementia Plans
- Country comparisons
- National Dementia Strategies (diagnosis, treatment and research)
- Austria
- Belgium
- Bulgaria
- Croatia
- Cyprus
- Czech Republic
- Denmark
- Estonia
- Finland
- France
- Germany
- Greece
- Hungary
- Ireland
- Italy
- Jersey
- Latvia
- Lithuania
- Luxembourg
- Malta
- Netherlands
- Norway
- Poland
- Portugal
- Romania
- Slovakia
- Slovenia
- Spain
- Sweden
- Switzerland
- Turkey
- United Kingdom (England)
- United Kingdom (Northern Ireland)
- United Kingdom (Scotland)
- United Kingdom (Wales)
- Acknowledgements
- Restrictions of freedom
- Austria
- Belgium
- Bulgaria
- Croatia
- Cyprus
- Czech Republic
- Denmark
- Estonia
- Finland
- France
- Germany
- Greece
- Hungary
- Iceland
- Ireland
- Italy
- Latvia
- Lithuania
- Luxembourg
- Malta
- Netherlands
- Norway
- Poland
- Portugal
- Romania
- Slovakia
- Slovenia
- Sweden
- Switzerland
- Turkey
- United Kingdom - England
- United Kingdom - Scotland
- Acknowledgements
- Legal capacity and proxy decision making
- Austria
- Belgium
- Bulgaria
- Czech Republic
- Denmark
- Estonia
- Finland
- France
- Germany
- Greece
- Hungary
- Iceland
- Ireland
- Italy
- Latvia
- Lithuania
- Luxembourg
- Malta
- Netherlands
- Norway
- Poland
- Portugal
- Romania
- Slovenia
- Spain
- Sweden
- Switzerland
- Turkey
- United Kingdom - England
- United Kingdom - Scotland
- Acknowledgements
- Healthcare and decision-making in dementia
- Austria
- Belgium
- Bulgaria
- Cyprus
- Czech Republic
- Denmark
- Estonia
- Finland
- France
- Germany
- Greece
- Hungary
- Iceland
- Ireland
- Italy
- Latvia
- Lithuania
- Luxembourg
- Malta
- Netherlands
- Norway
- Poland
- Portugal
- Slovakia
- Slovenia
- Spain
- Sweden
- Switzerland
- Turkey
- United Kingdom - England
- United Kingdom - Scotland
- Acknowledgements
- Home care
- Reimbursement of anti-dementia drugs
- Social support systems
- Austria
- Belgium
- Bulgaria
- Cyprus
- Czech Republic
- Denmark
- Estonia
- Finland
- France
- Germany
- Greece
- Hungary
- Iceland
- Ireland
- Italy
- Latvia
- Lithuania
- Luxembourg
- Malta
- Netherlands
- Norway
- Poland
- Portugal
- Romania
- Slovakia
- Slovenia
- Spain
- Sweden
- Switzerland
- Turkey
- United Kingdom - England
- United Kingdom - Scotland
- National Dementia Strategies (diagnosis, treatment and research)
- Our opinion on ...
- Advance directives
- Anti-dementia drugs
- Participation of people with dementia in clinical trials
- Policy on collaboration with other organisations
- Disclosure of the diagnosis to people with dementia and carers
- Genetic testing
- The Hague Convention for the International Protection of Adults
- Participation of people with dementia in research
- Stem Cell Research
- Ethics
- Dementia Ethics Network
- Definitions and approaches
- Ethical issues in practice
- The ethical issues linked to restrictions of freedom of people with dementia
- Preface
- Introduction
- Restriction of the freedom to choose one’s residence or place of stay
- Freedom to live in least restrictive environment
- The restriction of the freedom to act according to individual attitudes, values and lifestyle preferences
- The restriction of the freedom to play an active role in society
- Formal acknowledgements and disclaimer
- Appendices
- Glossary
- References
- Ethics of dementia research
- The dementia ethics research project
- Background, definitions and scope
- Involving people with dementia
- Informed consent to dementia research
- Protecting the wellbeing
- Risk, benefit, burden and paternalism
- Clinical trials
- Epidemiological research
- Genetic research
- Research into end-of-fe care
- The donation of brain and other tissue
- Publication and dissemination of research
- Glossary
- Annexes
- References
- The ethical issues linked to the use of assistive technology in dementia care
- End-of-Life care for people with dementia
- Advance directives and personhood
- The ethical issues linked to restrictions of freedom of people with dementia
- Research
- Value of Knowing
- European Collaboration on Dementia
- Cost of dementia
- The health economical context (Welfare theory)
- Health economic aspects of dementia
- The impact of informal care
- Cost of illness and burden of dementia
- Regional/National cost of illness estimates
- Prognosis to 2030
- Sensitivity analysis
- Other European cost of illness estimates
- Regional Patterns: The societal costs of dementia in Sweden
- Regional patterns: The economic environment of Alzheimer's disease in France
- Regional patterns: Economic environment of Alzheimer’s disease in Mediterranean countries
- Regional patterns: Socio-economic impact of dementia and resourse utilisation in Hungary
- Conclusions and policy implications
- Acknowledgements
- Diagnosis and treatment of dementia
- Prevalence of dementia
- Prevention of dementia
- Psychosocial interventions
- Social Support Systems
- Cost of dementia
- PharmaCog
- Comparative studies
- Understanding dementia research
- Conferences
- News
- Publications